CalciMedica Strengthens Executive Retention with Major CMO Stock Option Package

Rhea-AI Filing Summary

CalciMedica Chief Medical Officer Sudarshan Hebbar received a stock option grant for 83,300 shares of common stock on June 24, 2025. The options were granted with an exercise price of $1.53 per share and are immediately exercisable with an expiration date of April 22, 2035.

Key details of the transaction:

• The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval
• Stockholders approved the amended 2023 Equity Incentive Plan on June 24, 2025, finalizing the grant
• Options represent direct ownership and were granted under the company's Amended 2023 Equity Incentive Plan
• The filing was signed by John Dunn as attorney-in-fact on June 26, 2025

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hebbar Sudarshan

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD. #307

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.53	06/24/2025(1)		A		83,300		(2)	04/22/2035	Common Stock	83,300	$0	83,300	D

Explanation of Responses:

1. The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

2. Immediately exercisable.

	/s/ John Dunn, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did CALC's Chief Medical Officer receive in June 2025?

CALC's Chief Medical Officer, Sudarshan Hebbar, received 83,300 employee stock options (right to buy) on June 24, 2025, with an exercise price of $1.53 per share.

What is the exercise price of CALC CMO's stock options granted in June 2025?

The stock options granted to CALC's Chief Medical Officer have an exercise price of $1.53 per share.

When do CALC CMO Sudarshan Hebbar's stock options expire?

The stock options granted to CALC's Chief Medical Officer Sudarshan Hebbar expire on April 22, 2035.

Was CALC's June 2025 stock option grant subject to any special conditions?

Yes, the option grant was initially approved by CALC's Board of Directors on April 23, 2025, but was subject to stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan. The stockholders approved the amended plan on June 24, 2025.

Are the stock options granted to CALC's CMO immediately exercisable?

Yes, according to the Form 4 filing, the stock options granted to CALC's Chief Medical Officer are immediately exercisable.